FindTrial
Sign In

Effect of anti-helicobacter pylori therapy on IgA nephropathy in elderly patients

Effect of anti-helicobacter pylori therapy on IgA nephropathy in elderly patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019317
Enrollment
Unknown
Registered
2018-11-05
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

Group 2:Anti-HP therapy and conventional therapy for IgA nephropathy
Group 1:Routine treatment

Sponsors

The First Affiliated Hospital of Chengdu Medical College
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: C14 breath test confirmed Helicobacter pylori infection; Pathology confirmed IgA nephropathy; aged 15~75 years old

Exclusion criteria

Exclusion criteria: (1) patients with severe infection and heart failure, hypertension, diabetes, hypotension, and psychotic patients; (2) patients who unwilling to cooperate or fail to cooperate with the researchers in completing the complete collection of medical history data; (3) the combination of other immune diseases.

Design outcomes

Primary

MeasureTime frame
C14;Kidney pathology;24-Hour Urine Protein Quantification;Serum urinary nitrogen;Serum creatinine;Urine red blood cell count;—

Secondary

MeasureTime frame
blood pressure;—

Countries

China

Contacts

Public ContactFan Junming

The First Affiliated Hospital of Chengdu Medical College

junmingfan@163.com+86 13908199530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026